In the annual “Taiwan BIO Awards”, SunWay Biotech passed all the steps from the preliminary review to the final one by its multinational patents and strain-based market planning. SunWay Biotech has stood out from 55 biotechnology industry companies and awarded “Taiwan BIO Awards- Emerging Company of the Year“ in 2020!   BIO Asia-Taiwan 2020 International Conference & Exhibition SunWay Biotech company is awarded by President Tsai, Ing-Wen Professor Pan, Tzu-Ming introduced the history of SunWay Biotech company Speech of Professor Pan, Tzu-Ming Professor Pan, Tzu-Ming SunWay Biotech is awarded “Taiwan Bio Awards” in 2020.

The first clinical study, which has been published in the Journal of Food and Drug Analysis, documents that ANKASCIN® 568-R is effective in reducing subjects’ serum cholesterol and low-density lipoprotein cholesterol (LDL-C) to nearly desirable levels in as little as 4 weeks and were maintained in 8 weeks. Forty subjects (Inclusion criteria: LDL-C in the range of 130-190 mg/dL and serum cholesterol greater than 180 mg/dL) completed the double-blind, placebo-controlled randomized 12-week study. The administration group took 110 mg ANKASCIN® 568-R/one capsule/day for eight weeks. After four weeks of treatment (110 mg ANKASCIN® 568-R/day), the changes in the lipid levels showed that the active products had a more favorable effect than the placebo. Compared to the baseline, statistically significant decreases of 11.9% and 19.0% were observed in TC and LDL-C levels, respectively (p < 0.05 for all pairs). This study demonstrated that subjects administered 110 mg of ANKASCIN® 568-R for more than four weeks exhibited a significant reduction in serum TC and LDL-C levels. To assess the safety of this ingredient, scientists assayed aspartate transaminase (AST) and alanine aminotransferase (ALT) levels in the liver, and blood urea nitrogen (BUN), creatinine, and uric acid levels in the kidney. The results imply no significant effect on renal metabolism and physiological function. These results indicate that supplementation of ANKASCIN® 568-R reduces the risks of serum TC and […]

🌟 Exciting News! NIANGJIA Monascus Capsule is the first product of Taiwan recognized as a finalist for the Nutraingredient Asia Awards 2023: Botanical Product of the Year! 🌟 The specialty of #ANKASCIN568R is that it contains high levels of Monascin and Ankaflavin, showing anti-glycation, anti-inflammatory, and antioxidant abilities via #PPAR and #Nrf2 pathways to improve hyperglycemia, preventing fatty plaque accumulation for cardiovascular health, and ameliorating pathogenesis of Alzheimer’s decline to enhance cognitive function, having beneficial effects for healthy aging benefits. We are grateful to our dedicated R&D teams and the unwavering support from our valued customers. Let’s root for NIANGJIA Monascus Capsule to win the championship together! 💪 #NutraingredientAsia #Finalist #antiaging #CardiovascularHealth #BloodSugarManagement #NIUawards23 #RedYeastRice